Patient characteristics and biochemical findings during intravascular hemolysis after treatment with gemtuzumab ozogamicin.
| Case . | Age at GO treatment, y . | Sex . | Diagnose (FAB) . | GO dose, mg/m2 . | Time span from last GO to hemolysis episode, wk . | Assumed cause of intravascular hemolysis . | Free hemoglobin, μmol/L . | Reticulocytes, 109/L . | Lactate dehydrogenase, U/L . | C-reactive protein, nmol/L . | Haptoglobin, μmol/L . | Bilirubin, μmol/L . | Potassium, mmol/L . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt. 1 | 2 | M | AML (M4/M5) | 2 × 7.5 | 3 | Sepsis (Staphylococci) | 151-268 (< 3) | 6-20 (29-83) | 4118-7111 (105-205) | 1283-5212 (< 78) | 34.9-67.8 (2.9-20.0) | 13-22 (<22) | 2.3-5.8 (3.2-4.7) |
| Pt. 2 | 1 | F | AML (M5) | 2 × 5 | 5 | Unknown infection | 67-100 (< 3) | NT (29-83) | 1139-2103 (105-205) | 1333-4505 (< 78) | 26.0-41.4 (2.9-20.0) | 6-19 (<22) | 2.1-4.4 (3.2-4.7) |
| Case . | Age at GO treatment, y . | Sex . | Diagnose (FAB) . | GO dose, mg/m2 . | Time span from last GO to hemolysis episode, wk . | Assumed cause of intravascular hemolysis . | Free hemoglobin, μmol/L . | Reticulocytes, 109/L . | Lactate dehydrogenase, U/L . | C-reactive protein, nmol/L . | Haptoglobin, μmol/L . | Bilirubin, μmol/L . | Potassium, mmol/L . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt. 1 | 2 | M | AML (M4/M5) | 2 × 7.5 | 3 | Sepsis (Staphylococci) | 151-268 (< 3) | 6-20 (29-83) | 4118-7111 (105-205) | 1283-5212 (< 78) | 34.9-67.8 (2.9-20.0) | 13-22 (<22) | 2.3-5.8 (3.2-4.7) |
| Pt. 2 | 1 | F | AML (M5) | 2 × 5 | 5 | Unknown infection | 67-100 (< 3) | NT (29-83) | 1139-2103 (105-205) | 1333-4505 (< 78) | 26.0-41.4 (2.9-20.0) | 6-19 (<22) | 2.1-4.4 (3.2-4.7) |
Results are given as ranges during the periods of hemolysis. The local reference intervals are shown in parentheses.
FAB indicates French-American-British classification21 ; F, female; M, male; and NT, not tested.